<div style="border: 1px solid #000001; padding: 2px; margin-bottom: 5px;">
  <b>WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY</b>
  <br>
  <b>•Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life threatening pulmonary emobli, if administered intravenously.</b>
</div>
<br>
<b>IMPORTANT SAFETY INFORMATION</b>
<br>
<br>Prescription use of this product is limited under the Drug Addiction Treatment Act.<br><br>
<b>CONTRAINDICATIONS</b>
<br>
<br>
SUBLOCADE should not be administered to patients who have been shown to be hypersensitive to buprenorphine or any component of the ATRIGEL<sup>®</sup> delivery system
  <br><br><b>Please click here to full <a href="https://www.sublocade.com/Content/pdf/prescribing-information.pdf" target="blank">Prescribing Information
</a>, including BOXED WARNING</b>